Inova Diagnostics once again has its sights on rheumatoid arthritis-detecting technology, this week acquiring a novel platform developed at Hasselt University designed to identify autoantibody biomarkers for the debilitating condition.
With sales of eye drug Eylea growing at breakneck pace and a couple of promising candidates in its pipeline, Regeneron needs some more space.
Humira is the world's best-selling drug, bringing in $9.6 billion last year. The way drug information specialist EvaluatePharma sees it, AbbVie's ($ABBV) gem is going to remain the...
The FDA has approved Simponi in combination with methotrexate to treat moderately to severely active rheumatoid arthritis. The company points out that an estimated 1.3 million Americans and more than 23.5 million people worldwide suffer from RA.
Crescendo Bioscience won Medicare coverage for its rheumatoid arthritis molecular diagnostic, a major milestone and pivotal move in its bid to expand the test's market reach.
Amgen was delivered a nasty surprise about its superblockbuster Enbrel this week when a new study found that a cocktail of generics already on the market was as effective at treating rheumatoid arthritis.
AbbVie's rheumatoid arthritis drug Humira did exactly what the new company needed it to do in the first quarter. It returned significantly higher sales and allowed Abbvie to report better than expected earnings in its first earnings report as a stand-alone company.
Pfizer has big expectations for its oral rheumatoid arthritis treatment Xeljanz--about $3 billion worth. But those expectations were struck a serious blow when European Medicines Agency regulators Thursday turned it down for approval.
While the FDA continues its slow-motion release of new guidelines for producing biosimilars in the U.S., India's Cipla has stepped up with a knockoff of the rheumatoid arthritis blockbuster Enbrel, which it will sell in the subcontinent at a 30% discount.
Should taxpayers enjoy lower drug prices if federal money backed development? At least one U.S. senator thinks so, now that Pfizer has slapped a $2,000-per-month sticker price on the new rheumatoid arthritis drug Xeljanz.